Dear CCHMC Clinical Fellow,
Thank you for your interest in the Cincinnati Children's Hospital Medical Center Clinical Pharmacology Fellowship. This application is specific to clinical fellows already enrolled in a CCHMC Clinical Fellowship. Please see the other application for post-doctoral applicants who are not clinical fellows at CCHMC. To apply for the program, we request the following items:

1) Curriculum Vitae
2) Three letters of recommendation; if possible, at least one letter should be from a potential mentor for your proposed projects (does not need to be a translational and clinical pharmacology faculty member); one should be from your clinical fellowship director.
a. Of note, a mentor agreement will need to be completed and signed around the time of appointment.
3) One-to-two-page personal statement highlighting why you are interested in the fellowship and potential projects (latter is non-binding)
4) Individual Development Plan: The Office of Academic Affairs and Development has a template for faculty that can be adapted for this purpose, but the applicant can design their own. We would like to see the following in the plan:
a. Research Goals
b. Educational Goals
c. Career Development Goals

Please provide a brief description about each goal and plans to achieve these goals (e.g. IRB submission, publications, classes, workshops, hands-on training experiences)
5) Commitment for $75 \%$ protected time: to be signed by applicant, mentor(s), clinical fellowship program director, division director and divisional business director (see final page)

Components that will be evaluated include, but are not limited to:

- Academic credentials, previous research experience, proposed projects for fellowship, individual development plan, current/proposed mentorship team, letters of support, leadership potential

While not required, it would be appreciated if the applicant could send an email of intent to apply to the Program Directors, Drs. Sonya Tang Girdwood and Tracy Glauser, and the Program Administrator, Ms. Ana Madani. This process will allow the directors to gather the application review committee in a timely fashion so that a decision can be made by early April.

To be considered for a July position, all application materials must be received by March 1 ( 5 pm EST) of the same year. Please combine all application components into one PDF and email Ms. Ana Madani and Drs. Sonya Tang Girdwood and Tracy Glauser.

If you have any questions, please do not hesitate to contact the Program Directors or Administrator.

Sincerely,


Sonya Tang Girdwood, MD, PhD
Sonya.TangGirdwood@cchmc.org


Tracy Glauser, MD
Tracy.Glauser@cchmc.org

Commitment to 75\% Protection to Clinical Pharmacology Scholarly Activities and Research As of early 2024, there will be TWO T32-funded clinical pharmacology fellowship positions open in July 2024. For applicants interested in pursuing a clinical pharmacology fellowship from July 2024-June 2026, there are two potential funding pathways.

## Pathway A: T32-funded

July 2024-June 2026
a. Salary support provided by NICHD T32 funding- please note salary is determined by level of training and dictated by the NICHD (NOT-OD-23-076: Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2023 (nih.gov)) (subject to change when FY 2024 levels are released); clinical fellows may need their division to provide additional salary support so their salary meets their PGY clinical training level
b. Training-related expenses, travel funds (NICHD annual meeting, ASCPT), courses \& fees funds provided by NICHD T32 funding ( $\sim \$ 10,000$ )

## Pathway B: Clinical Division-funded

Fellows under this pathway will receive the same training as the T32-funded fellows and have similar opportunities, including being recognized by the NICHD Pediatric Clinical Pharmacology Training Network. July 2024-June 2026
a. Full salary support provided by Clinical Division
b. Training-related expenses, travel funds (NICHD annual meeting, ASCPT), courses \& fees funds provided by Clinical Division and/or mentor (as a reference, the T32 provides $\sim \$ 10,000$ )*
*There is a possibility, but no guarantee, that the Translational and Clinical Pharmacology division may be able to assist with some of these costs. Further discussions will be held with the new Translational \& Clinical Pharmacology Division Director.

Based on the application and the responses on the next page, the following decisions may be made:

1. Accept to the Clinical Pharmacology Fellowship Program under Pathway A
2. Accept to the Clinical Pharmacology Fellowship Program under Pathway B
3. Cannot accept to the Clinical Pharmacology Fellowship Program at this time

If you, your program director, division director, business director or mentors have any questions about the funding pathways, please do not hesitate to contact Drs. Tang Girdwood and/or Glauser so we can set up a meeting to discuss further before the application is due.

Please complete this form to be included with your final application. Part two requires a selection to be made.
Part one: T32-funded Pathway A
We, the undersigned, agree for $\qquad$ (fellow name) to commit 75\% of their time to the Clinical Pharmacology fellowship from July 2024 through June 2026. The Division of $\qquad$ will supplement the T32 provided salary to ensure equitable salary for the fellow as compared their clinical co -fellows at the same PGY-level.

The $25 \%$ clinical time is outlined as follows (please include number of weeks on inpatient services, days per week in outpatient clinic, number of overnight calls/month, time for procedures, etc):

25\% clinical time:
$1^{\text {st }}$ year of Clinical Pharmacology fellowship:
$2^{\text {nd }}$ year of Clinical Pharmacology fellowship (if different, explain why):

## Name

Signature
Date
Applicant
Fellowship Program Director
Division Director
Business Director
Mentor(s)

Part two: Pick one by placing initials of applicant (AP), fellowship program director (PD), division director (DD) business director (BD) and mentor(s) (M) under choice and signing below:

Clinical Division-Supported (Pathway B): If selected for the clinical pharmacology fellowship but not the T32-funded positions, we, the undersigned, agree for $\qquad$ (fellow name) to commit $75 \%$ of their time to the Clinical Pharmacology fellowship from July 2024 through June 2026 ( $25 \%$ clinical as outlined in Part one). The Division of $\qquad$ will provide full salary support from July 2024 through June 2026. The division and/or mentors will provide resources and funds to allow for the proposed fellowship projects to be executed and for travel to the annual NICHD Pediatric Clinical Pharmacology Training meeting and to the American Society of Clinical Pharmacology of Therapeutics Annual Meeting for each year.

Pathway B initials: $\qquad$ (AP) $\qquad$ (PD) $\qquad$ (DD) $\qquad$ (BD) $\qquad$ (M1) $\qquad$ (M2, optional)

Unsupported: If selected for the clinical pharmacology fellowship but not for the T32-funded positions for July 2024-June 2026, we will not be able commit the time nor the funds for the fellow to commit to a 2-year clinical pharmacology fellowship (July 2024-June 2026).

Unsupported initials: $\qquad$ (AP) $\qquad$ (PD) $\qquad$ (DD) $\qquad$ (BD) $\qquad$ (M1) $\qquad$ (M2, optional)

Name
Signature
Date:
Applicant
Fellowship Program Director
Division Director
Business Director
Mentor(s) providing funds

